Karel Cwiertka

696 total citations
45 papers, 436 citations indexed

About

Karel Cwiertka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Karel Cwiertka has authored 45 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in Karel Cwiertka's work include HER2/EGFR in Cancer Research (9 papers), Breast Cancer Treatment Studies (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Karel Cwiertka is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Breast Cancer Treatment Studies (8 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Karel Cwiertka collaborates with scholars based in Czechia, United Kingdom and Poland. Karel Cwiertka's co-authors include Marián Hajdúch, Kateřina Bouchalová, Radek Trojanec, Magdalena Čížková, G. Bodoky, Jana Prausová, David Vrána, Wolfgang Fischbach, Stephan Haas and Manfred P. Lutz and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Karel Cwiertka

45 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karel Cwiertka Czechia 10 247 123 115 108 48 45 436
Dimitrios Tryfonopoulos Greece 12 269 1.1× 96 0.8× 176 1.5× 119 1.1× 79 1.6× 46 627
Minsig Choi United States 14 360 1.5× 134 1.1× 190 1.7× 104 1.0× 82 1.7× 28 549
Hae Su Kim South Korea 12 270 1.1× 173 1.4× 147 1.3× 92 0.9× 78 1.6× 26 511
Tomoyuki Aruga Japan 13 230 0.9× 132 1.1× 71 0.6× 161 1.5× 50 1.0× 59 403
Jane‐Chloé Trone France 10 165 0.7× 142 1.2× 150 1.3× 107 1.0× 74 1.5× 43 501
Ted Shih United States 6 222 0.9× 86 0.7× 201 1.7× 92 0.9× 31 0.6× 9 524
Gillian Bethune Canada 8 222 0.9× 149 1.2× 189 1.6× 119 1.1× 47 1.0× 18 483
Giuseppe Gullo Ireland 13 368 1.5× 151 1.2× 271 2.4× 154 1.4× 59 1.2× 42 692
Emma Kipps United Kingdom 8 292 1.2× 94 0.8× 268 2.3× 157 1.5× 70 1.5× 26 693
Erion Dobi France 14 217 0.9× 147 1.2× 74 0.6× 111 1.0× 36 0.8× 31 356

Countries citing papers authored by Karel Cwiertka

Since Specialization
Citations

This map shows the geographic impact of Karel Cwiertka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karel Cwiertka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karel Cwiertka more than expected).

Fields of papers citing papers by Karel Cwiertka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karel Cwiertka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karel Cwiertka. The network helps show where Karel Cwiertka may publish in the future.

Co-authorship network of co-authors of Karel Cwiertka

This figure shows the co-authorship network connecting the top 25 collaborators of Karel Cwiertka. A scholar is included among the top collaborators of Karel Cwiertka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karel Cwiertka. Karel Cwiertka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Majera, Dušana, Zdeněk Škrott, Jan Bouchal, et al.. (2018). Targeting genotoxic and proteotoxic stress‐response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram. The Prostate. 79(4). 352–362. 24 indexed citations
2.
Adam, Tomáš, Lenka Kujovská Krčmová, Dagmar Solichová, et al.. (2016). Prognostic Significance of Serum and Urinary Neopterin Concentrations in Patients with Rectal Carcinoma Treated with Chemoradiation.. PubMed. 36(1). 287–92. 7 indexed citations
3.
4.
Vrána, David, Jiří Gatěk, Pavel Koranda, et al.. (2014). Predictive parameters for internal mammary node drainage in patients with early breast cancer.. PubMed. 100(3). 254–8. 7 indexed citations
5.
Vrána, David, et al.. (2013). Internal mammary node management in breast cancer. A review. Biomedical Papers. 157(3). 261–265. 6 indexed citations
6.
Cwiertka, Karel, Hana Študentová, Č Neoral, et al.. (2012). Prognostic Significance of Serum Neopterin in Patients with Esophageal Carcinoma. SHILAP Revista de lepidopterología. 23(1). 22–26. 3 indexed citations
7.
Skalický, Pavel, et al.. (2011). The significance of portal vein embolization in the treatment of colorectal liver metastases. Neoplasma. 59(2). 175–182. 2 indexed citations
8.
Löhr, Matthias, Stephan Haas, Wolf O. Bechstein, et al.. (2011). Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Annals of Oncology. 23(5). 1214–1222. 80 indexed citations
9.
Bouchalová, Kateřina, Radek Trojanec, Marta Dziechciarková, et al.. (2010). Abstract P2-09-30: Impact of PIK3CA, PTEN and RPS6 Status on Lapatinib Treatment Outcome in Advanced-Stage Breast Cancer Patients. Cancer Research. 70(24_Supplement). P2–9. 2 indexed citations
10.
Bouchalová, Kateřina, Magdalena Čížková, Karel Cwiertka, et al.. (2010). LAPATINIB IN BREAST CANCER - THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT. Biomedical Papers. 154(4). 281–288. 19 indexed citations
11.
Hajdúch, Marián, et al.. (2010). Repeated chemosensitivity testing in patients with epithelial ovarian carcinoma.. PubMed. 31(3). 295–8. 1 indexed citations
12.
Capri, Giuseppe, José Chang, Pierfranco Conté, et al.. (2009). An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Annals of Oncology. 21(3). 474–480. 64 indexed citations
13.
Melichar, Bohuslav, Hana Študentová, Eva Malířová, et al.. (2009). Serum Neopterin, Retinol and Alpha-tocopherol in Patients with the Carcinoma of the Esophagus. Pteridines. 20(1). 49–53. 1 indexed citations
14.
Beneš, Petr, et al.. (2009). Serum Neopterin in Patients with Malignant Melanoma. Pteridines. 20(1). 45–48. 1 indexed citations
15.
Bouchalová, Kateřina, Magdalena Čížková, Karel Cwiertka, Radek Trojanec, & Marián Hajdúch. (2009). Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomedical Papers. 153(1). 13–17. 42 indexed citations
16.
Skalický, Pavel, et al.. (2009). Radiofrequenzablation von kolorektalen Lebermetastasen. Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie. 134(2). 145–148. 6 indexed citations
17.
Cwiertka, Karel, et al.. (2008). PSEUDOANGIOMATOUS STROMAL HYPERPLASIA OF BREAST: A CASE REPORT. Biomedical Papers. 152(1). 117–120. 5 indexed citations
18.
19.
Robová, Helena, Lukáš Rob, H Stankusová, et al.. (2004). [Guideline for gynecological malignant tumors 2004--primary complex therapy in operable stages of malignant tumors of vulva].. PubMed. 69(6). 477–83. 1 indexed citations
20.
Koranda, Pavel, et al.. (2004). Technetium-99m-MIBI scintimammography by planar and SPECT imaging in the diagnosis of breast carcinoma and axillary lymph node involvement.. PubMed. 7(2). 151–5. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dimitrios Tryfonopoulos Breakdown of academic impact, for papers by Minsig Choi Breakdown of academic impact, for papers by Hae Su Kim Breakdown of academic impact, for papers by Tomoyuki Aruga Breakdown of academic impact, for papers by Jane‐Chloé Trone Breakdown of academic impact, for papers by Ted Shih Breakdown of academic impact, for papers by Gillian Bethune Breakdown of academic impact, for papers by Giuseppe Gullo Breakdown of academic impact, for papers by Emma Kipps Breakdown of academic impact, for papers by Erion Dobi
Rankless by CCL
2026